^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    DetermaTx™

    Company:
    Oncocyte
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    over2years
    DetermaTx™: Clinical launch in Q1 2023 (Oncocyte)
    Investor Presentation
    Launch
    |
    DetermaTx™
    almost3years
    DetermaIO +DetermaTx launch estimate: For genomic profiling test in late Q1 2022 (GlobalData)
    A subscription to REFINITIV is required to access document 95105979 | Page no: 81 | REPORT TITLE: "OncoCyte Corp (OCX) - Financial analysis review” | AUTHOR: Global Data, et al | DATE: 01/11/22
    Launch
    |
    DetermaIO™ • DetermaTx™
    almost3years
    DetermaTx™: Reimbursement dossier submission by end of Q2 2022 (Oncocyte)
    Investor Presentation
    Reimbursement
    |
    DetermaTx™
    almost3years
    DetermaTx™: Clinical launch in 1H22 (Oncocyte)
    Investor Presentation
    Launch
    |
    DetermaTx™
    almost3years
    DetermaTx launch estimate: For tumor detection in Q1 2022 (GlobalData)
    A subscription to REFINITIV is required to access document 94034972 | Page no: 108 | REPORT TITLE: "OncoCyte Corp (OCX) - Financial analysis review” | AUTHOR: GlobalData, et al | DATE: 12/07/21
    Launch
    |
    DetermaTx™
    almost3years
    DetermaTx launch estimate: For tumor detection in H1 2022 (The Benchmark Company)
    "A subscription to REFINITIV is required to access document 94587787 | Page no: 01 | REPORT TITLE: "Model update for 3Q; Robust 2022 product launch schedule” | AUTHOR: Bruce D. Jackson, et al | DATE: 11/16/21"
    Launch
    |
    DetermaTx™